Bioequivalence Study of Two Products of Apremilast 30 mg Tablets in Healthy, Adult, Human Subjects

NCT ID: NCT06084663

Last Updated: 2023-12-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-02-15
• Study Completion Date: 2023-04-25

Brief Summary

An open label, balanced, randomized, two-sequence, two-treatment, two-period, single oral dose, crossover, bioequivalence study in normal, healthy, adult, human subjects under fasting condition

Conditions

Psoriasis and Psoriatic Arthritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Apremilast 30 mg Tablets

One tablet was administered orally to each subject as per randomization schedule in each period

Group Type: EXPERIMENTAL

Apremilast 30 mg Tablets

Intervention Type: DRUG

Each film-coated tablet contains 30 mg of apremilast

Otezla 30 mg film-coated tablets

Intervention Type: DRUG

Each film-coated tablet contains 30 mg of apremilast

Otezla 30 mg film-coated tablets

One tablet was administered orally to each subject as per randomization schedule in each period

Group Type: ACTIVE_COMPARATOR

Apremilast 30 mg Tablets

Intervention Type: DRUG

Each film-coated tablet contains 30 mg of apremilast

Otezla 30 mg film-coated tablets

Intervention Type: DRUG

Each film-coated tablet contains 30 mg of apremilast

Interventions

Apremilast 30 mg Tablets

Each film-coated tablet contains 30 mg of apremilast

Intervention Type: DRUG

Otezla 30 mg film-coated tablets

Each film-coated tablet contains 30 mg of apremilast

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Non-smoker, Normal, healthy, adult, human, subjects between 18 and 45 years of age (both inclusive).
• Having a Body Mass Index (BMI) between 18.5 to 30.0 (both inclusive), calculated as weight in kg/height in m2.
• Not having significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination, laboratory evaluations, 12 lead ECG, and chest X-ray recordings (P/A view).
• Able to understand and comply with the study procedures, in the opinion of the investigator.
• Able to give voluntary written informed consent for participation in the trial.
• In case of female subjects:

Surgically sterilized at least 6 months prior to study participation. Or If of child bearing potential is willing to use a suitable and effective double barrier contraceptive method or intra uterine device during the study.

And Serum pregnancy test must be negative.

Exclusion Criteria

• History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
• Ingestion or Use of medication [non-prescribed systemic or topical medication (including vitamin/mineral supplements, and herbal medicines)] at any time from 14 days prior to dosing of period-I and Use of any prescribed systemic or topical medication from 30 days prior to dosing of period-I and any vaccine (including COVID-19 vaccine) within 14 days prior to dosing of period-I. In any such case subject selection will be at the discretion of the Principal Investigator.
• Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAIDs induced urticaria.
• Consumption of grapefruits or its products within a period of 72 hours prior to dosing of period-I.
• Smokers or who have smoked within last 06 months prior to start of the study.
• A recent history of harmful use of alcohol (less than 2 years), i.e. alcohol consumption of more than 14 standard drinks per week for men and more than 7 standard drinks per week for women (A standard drink is defined as 360 mL of beer or 150 mL of wine or 45 ml of 40% distilled spirits, such as rum, whisky, brandy etc) or consumption of alcohol or alcoholic products within 48 hours prior to dosing of period-I.
• The presence of clinically significant abnormal laboratory values during screening.
• Use of any recreational drugs or history of drug addiction or testing positive in pre study drug scans.
• History or presence of seizure or psychiatric disorder
• A history of difficulty with donating blood.
• Donation of blood (1 unit or 350 mL) within a period of 90 days prior to the first dose of study medication.
• Receipt of an investigational medicinal product or participation in a drug research study within a period of 90 days prior to the first dose of study medication**.
• ** If investigational medicinal product is received within 90 days where there is no blood loss except safety lab testing, subject can be included considering 10 half-lives duration of investigational medicinal product received.
• Difficulty in swallowing tablet or oral solid dosage form
• A positive hepatitis screen including hepatitis B surface antigen and/or HCV antibodies.
• A positive test result for HIV antibody (1 &/or 2).
• An unusual diet, for whatever reason (for example, fasting, high potassium or low-sodium), for four weeks prior to receiving the study drug in period I. In any such case subject selection will be at the discretion of the Principal Investigator.
• Hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.
• Any condition which places the subject at unacceptable risk if he/she were to participate in the study, or confounds the ability to interpret data from the study.
• Any surgical or medical condition possibly affecting drug absorption, distribution, metabolism and excretion, eg, bariatric procedure, colon resection, irritable bowel syndrome, Crohn's disease, etc.
• The QTc interval more than 450 msec for male subjects and 460 msec for female subjects at the time of screening.
• Nursing mothers (for female subjects).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Humanis Saglık Anonim Sirketi

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hakan Gürpınar

Role: STUDY_DIRECTOR

Humanis Saglık

Locations

Lambda Therapeutic Research Ltd.

Ahmedabad, Gujarat, India

Countries

India

Other Identifiers

0005-22

Identifier Type: -

Identifier Source: org_study_id